StockData
OrthoPediatrics Corp logo

OrthoPediatrics Corp (KIDS) company profile

KIDSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 11/308% below fair value
$31.65+0.24 (+0.76%)

Close on Nov 18, 2026Market cap $826.40MP/E –Yield –

About OrthoPediatrics

Surgical & Medical Instruments & Apparatus, SIC 3841

OrthoPediatrics Corp. is a medical device company that develops, manufactures, and markets anatomically appropriate implants, surgical instruments, and specialized bracing products for children with orthopedic conditions. The company also provides non-surgical clinical care through a network of orthotic and prosthetic clinics. Its offerings address three primary categories: trauma and deformity correction, scoliosis, and sports medicine. OrthoPediatrics designs its systems to accommodate pediatric anatomy and protect children's growth plates, serving pediatric orthopedic surgeons, caregivers, and pediatric hospitals.

The company is headquartered in Warsaw, Indiana. It sells its systems in the United States and across more than 75 international countries, operating direct sales channels, independent agencies, and stocking distributor networks. Additionally, the company maintains operating entities and facilities in multiple countries, including warehouses in Australia, Germany, and the Netherlands, alongside orthotic and prosthetic clinics in various United States locations and Ireland.

Summary of the business section of OrthoPediatrics's latest annual report, written by StockData.

Company profile

Company

Legal name
OrthoPediatrics Corp
Founded
2006
Headquarters
Warsaw, IN
Address
2850 Frontier Drive 46582
Phone
(574) 268-6379
Employees
602, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Indianapolis, Indiana

Stock & identifiers

Ticker
KIDS
Exchange
Nasdaq
IPO date
Oct 12, 2017
Shares outstanding
26M, Oct 27, 2026
Public float
$362.50M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1425450
CUSIP
68752L100
ISIN
US68752L1008
FIGI
BBG00HFFRW39
Share class FIGI
BBG00HFFRW48
LEI
5493000KUTPFGOPAT717
EIN
26-1761833

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David R. BaileyPresident and CEO, Director417,160
Fred HiteCOO and CFO, Director277,477
Daniel J. GerritzenGeneral Counsel and Secretary147,054
Gregory A. OdlePresident of Scoliosis187,735
Joseph W. HauserPres. Trauma & Def. Correction194,767
David R. PelizzonDirector6,246,148
Kelly Laine FischerDirector15,781
Mark C. ThrodahlDirector201,814
Samuel D. RiccitelliDirector31,859
(Reynolds) Marie C. InfanteDirector31,202
Bryan W. HughesDirector32,663
Jimmy Duane McDonaldDirector24,568
George Sinclair Mitchell DyerDirector24,568
Harold RufDirector22,237
Terry D. SchlotterbackDirector29,165

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.33M$1.92M$1.84M$30$75000
FY2024$3.66M$2.47M$1.88M$56$75000
FY2023$2.72M$2.21M$1.52M$79$72000
FY2022$1.28M$826.32K$1.09M$96$75000
FY2021
David RBailey
$906.05K$1.46M$784.91K$145$100000
FY2021
Mark C.Throdahl
$718.03K$1.38M$784.91K$145$100000

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
David R. Bailey
President and Chief Executive Officer
$550.00K$2.45M$322.28K$14.00K$3.33M-9%
Fred L. Hite
Chief Operating Officer and Chief Financial Officer
$501.00K$1.59M$293.57K$14.00K$2.40M-7%
Gregory A. Odle
President of Scoliosis
$368.00K$972.43K$143.76K$14.00K$1.50M-6%
Daniel J. Gerritzen
Executive Vice President (Legal), General Counsel, and Secretary
$368.00K$972.43K$143.76K$12.88K$1.50M-6%
Joseph W. Hauser
President of Trauma, Deformity and OPSB
$413.00K$1.31M$239.46K$14.00K$1.97M+14%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 12, 2017
Offer price
$13.00
Securities offered
4,000,000
Gross proceeds
$52.00M
Exchange
Nasdaq
Lock-up ends (est.)
Apr 10, 2018

“​ • The initial public offering price is $13.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 602 full-time employees, 43 of whom were engaged in research and development and 109 of whom were engaged in sales and marketing.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?